Cargando…
Resistant social anxiety disorder response to Escitalopram
BACKGROUND: Social Anxiety Disorder (SAD) is a common disorder and its high prevalence and lifelong chronicity are such that it represents a substantial public health problem. The observation that serotonergic agents appear to be effective for its treatment suggests that patients may have abnormal s...
Autores principales: | Pallanti, Stefano, Quercioli, Leonardo |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1769378/ https://www.ncbi.nlm.nih.gov/pubmed/17166264 http://dx.doi.org/10.1186/1745-0179-2-35 |
Ejemplares similares
-
Pharmacogenetically Guided Escitalopram Treatment for Pediatric Anxiety Disorders: Protocol for a Double-Blind Randomized Trial
por: Strawn, Jeffrey R., et al.
Publicado: (2021) -
Protocol for Escitalopram and Language Intervention for Subacute Aphasia (ELISA): A randomized, double blind, placebo-controlled trial
por: Stockbridge, Melissa D., et al.
Publicado: (2021) -
Long-term administration of escitalopram in patients with social anxiety disorder in Japan
por: Asakura, Satoshi, et al.
Publicado: (2016) -
Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial
por: Zhou, Jingjing, et al.
Publicado: (2019) -
Internet treatment for social anxiety disorder in Romania: study protocol for a randomized controlled trial
por: Tulbure, Bogdan Tudor, et al.
Publicado: (2012)